TPGS2

Across TCGA pan-cancer cohorts, TPGS2 RNA differs between tumor and matched normal tissue in 11 of 18 cancer types tested, making tumor–normal expression one of TPGS2’s most consistent transcriptional readouts.

The strongest signal is observed in liver hepatocellular carcinoma (LIHC), where TPGS2 RNA is more highly expressed in tumor relative to normal tissue. In most cancer types TPGS2 is over-expressed in tumor, although a few such as KICH and KIRC show the opposite, repressed pattern.

LIHC, HNSC, and BLCA are the cancer types where TPGS2 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in TPGS2 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
LIHC	Female	II,III,IV	+1.348	<.001	9	view →
HNSC	Male	All	+0.731	<.001	8	view →
BLCA	Female	III,IV	+0.765	.005	6	view →
UCEC	All	All	+0.735	<.001	6	view →
CHOL	Female	All	+3.156	<.001	5	view →
READ	All	III,IV	+0.645	.013	5	view →
STAD	Male	All	+0.610	.001	4	view →
LUSC	All	All	+0.551	<.001	4	view →
KICH	All	All	−0.531	<.001	4	view →
COAD	All	All	+0.283	.006	3	view →
KIRC	Male	II,III,IV	−0.283	.025	2	view →
COAD	Female	IV	−1.075	.021	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 12 strongest of 11 lineages.

TPGS2–LIHC

Open the LIHC breakdown →